201 related articles for article (PubMed ID: 17276408)
1. Calcium channel antagonists: clinical uses--past, present and future.
Triggle DJ
Biochem Pharmacol; 2007 Jun; 74(1):1-9. PubMed ID: 17276408
[TBL] [Abstract][Full Text] [Related]
2. Ca2+ channel subtypes and pharmacology in the kidney.
Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
[TBL] [Abstract][Full Text] [Related]
3. Drug targets in the voltage-gated calcium channel family: why some are and some are not.
Triggle DJ
Assay Drug Dev Technol; 2003 Oct; 1(5):719-33. PubMed ID: 15090244
[TBL] [Abstract][Full Text] [Related]
4. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain.
Winquist RJ; Pan JQ; Gribkoff VK
Biochem Pharmacol; 2005 Aug; 70(4):489-99. PubMed ID: 15950195
[TBL] [Abstract][Full Text] [Related]
5. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.
Takahara A
Cardiovasc Ther; 2009; 27(2):124-39. PubMed ID: 19426250
[TBL] [Abstract][Full Text] [Related]
6. Chronic morphine treatment decreases the Cav1.3 subunit of the L-type calcium channel.
Haller VL; Bernstein MA; Welch SP
Eur J Pharmacol; 2008 Jan; 578(2-3):101-7. PubMed ID: 18048029
[TBL] [Abstract][Full Text] [Related]
7. Cardiology in the 1980s.
Brest AN
Clin Ther; 1982; 5(2):98-100. PubMed ID: 6130843
[No Abstract] [Full Text] [Related]
8. [Molecular effects of new calcium antagonists: is the principle of parcimony out of place?].
Richard S; Virsolvy A; Fort A
Ann Cardiol Angeiol (Paris); 2008 Jun; 57(3):166-73. PubMed ID: 18565491
[TBL] [Abstract][Full Text] [Related]
9. [The role of new dihydropyridine calcium channel blockers in the treatment of hypertension].
Coca A
An Med Interna; 2003 Jun; 20(6):279-81. PubMed ID: 12848596
[No Abstract] [Full Text] [Related]
10. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
[TBL] [Abstract][Full Text] [Related]
11. CSTX-1, a toxin from the venom of the hunting spider Cupiennius salei, is a selective blocker of L-type calcium channels in mammalian neurons.
Kubista H; Mafra RA; Chong Y; Nicholson GM; Beirão PS; Cruz JS; Boehm S; Nentwig W; Kuhn-Nentwig L
Neuropharmacology; 2007 Jun; 52(8):1650-62. PubMed ID: 17517422
[TBL] [Abstract][Full Text] [Related]
12. Neuropsychiatric manifestations of cardiovascular drug therapy.
Keller S; Frishman WH; Epstein J
Heart Dis; 1999; 1(4):241-54. PubMed ID: 11720631
[TBL] [Abstract][Full Text] [Related]
13. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes.
Furukawa T; Nukada T; Namiki Y; Miyashita Y; Hatsuno K; Ueno Y; Yamakawa T; Isshiki T
Eur J Pharmacol; 2009 Jun; 613(1-3):100-7. PubMed ID: 19401195
[TBL] [Abstract][Full Text] [Related]
14. [Calcium channel blockers. Review and attempt at classification].
van Zwieten PA; Timmermans PB
Rev Esp Cardiol; 1984; 37(5):322-9. PubMed ID: 6387828
[No Abstract] [Full Text] [Related]
15. [The range of clinical use of current calcium antagonists].
Sidorenko BA; Preobrazhenskiĭ LV
Ter Arkh; 1998; 70(12):80-4. PubMed ID: 10067262
[No Abstract] [Full Text] [Related]
16. PKCepsilon upregulates voltage-dependent calcium channels in cultured astrocytes.
Burgos M; Pastor MD; González JC; Martinez-Galan JR; Vaquero CF; Fradejas N; Benavides A; Hernández-Guijo JM; Tranque P; Calvo S
Glia; 2007 Nov; 55(14):1437-48. PubMed ID: 17676593
[TBL] [Abstract][Full Text] [Related]
17. Linking calcium-channel isoforms to potential therapies.
Belardetti F; Zamponi GW
Curr Opin Investig Drugs; 2008 Jul; 9(7):707-15. PubMed ID: 18600576
[TBL] [Abstract][Full Text] [Related]
18. Site-directed antibodies to low-voltage-activated calcium channel CaV3.3 (alpha1I) subunit also target neural cell adhesion molecule-180.
Chen Y; Sharp AH; Hata K; Yunker AM; Polo-Parada L; Landmesser LT; McEnery MW
Neuroscience; 2007 Mar; 145(3):981-96. PubMed ID: 17317015
[TBL] [Abstract][Full Text] [Related]
19. A small-molecule screen in C. elegans yields a new calcium channel antagonist.
Kwok TC; Ricker N; Fraser R; Chan AW; Burns A; Stanley EF; McCourt P; Cutler SR; Roy PJ
Nature; 2006 May; 441(7089):91-5. PubMed ID: 16672971
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
